Test reveals effectiveness of potential Huntington's disease drugs

Oct 30, 2006
Test reveals effectiveness of potential Huntington's disease drugs
Researchers led by Dr. Ilya Bezprozvanny, associate professor of physiology, and including Dr. Jun Wu, research associate, have shown an effective test for screening Huntington's disease drugs and that two compounds -- memantine and riluzole -- are most effective at keeping cells alive under conditions that mimic the disorder. Credit: UT Southwestern Medical Center

A test using cultured cells provides an effective way to screen drugs against Huntington's disease and shows that two compounds – memantine and riluzole – are most effective at keeping cells alive under conditions that mimic the disorder, UT Southwestern Medical Center researchers report.

"These drugs have been tested in a variety of Huntington's disease models and some HD human trials and results are very difficult to interpret," said Dr. Ilya Bezprozvanny, associate professor of physiology and senior author of the study, available online and published in today's issue of Neuroscience Letters. "For some of these drugs conflicting results were obtained by different research groups, but it is impossible to figure out where the differences came from because studies were not conducted in parallel.

"We systematically and quantititatively tested the clinically relevant drugs side-by-side in the same HD model. That has never been done before," said Dr. Bezprozvanny.

Huntington's disease is a fatal genetic disorder, manifesting in adulthood, in which certain brain cells die. The disease results in uncontrolled movements, emotional disturbance and loss of mental ability. The offspring of a person with Huntington's have a 50 percent chance of inheriting it.

More than 250,000 people in the United States have the disorder or are at risk for it. There is no cure, but several drugs are used or are being tested to relieve symptoms or slow Huntington's progression.

The disease affects a part of the brain called the striatum, which is involved in the control of movement and of "executive function," or planning and abstract thinking. It primarily attacks nerve cells called striatal medium spiny neurons, the main component of the striatum.

Dr. Bezprozvanny's group previously demonstrated that Huntington's striatal neurons are oversensitive to glutamate, a compound that nerve cells use to communicate with each other.

In the latest UT Southwestern study, the researchers cultured striatal spiny neurons from the brains of mice genetically engineered to express the mutant human Huntington gene. As predicted, glutamate killed the Huntington's neurons, but the scientists also tested five clinically relevant glutamate inhibitors to assess their protective ability.

Folic acid has been suggested as a treatment for people with Huntington's because it interacts with homocysteine, a compound that makes nerve cells more vulnerable to glutamate. Gabapentin and lamotrigine, both glutamate inhibitors, are used in epilepsy treatment and as a mood stabilizer, respectively. These three compounds did not significantly protect the cultured cells.

However, a drug called memantine, which is used to treat Alzheimer's disease, and riluzole, used in amyotrophic lateral sclerosis, did protect the cells. Memantine demonstrated a stronger effect in the study. Memantine has also shown evidence of retarding the progression of Huntington's in people, while riluzole has helped relieve some symptoms.

"Our results provide the first systematic comparison of various clinically relevant glutamate pathway inhibitors for HD treatment and indicate that memantine holds the most promise based on its in vitro efficacy," Dr. Bezprozvanny said. "Whole animal studies of memantine in an HD mouse model will be required to validate these findings."

Source: UT Southwestern Medical Center

Explore further: Simpler antibiotic treatments could help millions of infants who lack access to hospitals

Related Stories

Light technologies illuminate global challenges

Jan 13, 2015

During these dark winter months, spare a thought for artificial lights. From strings of lights adding holiday cheer to artificial sunlamps alleviating seasonal affective disorder, they brighten our days. ...

Sensor demonstrates lack of space in living cells

Jan 05, 2015

Proteins and other bio molecules are often analysed exclusively in aqueous solutions in test tubes. But it is uncertain if these experimental studies can be transferred to the densely-packed cellular environment. ...

Recommended for you

Outcomes no worse for macrolide-resistant pneumonia

4 hours ago

(HealthDay)—For patients with Streptococcus pneumoniae pneumonia, macrolide-resistance is not associated with worse outcomes, according to a study published online March 25 in the American Journal of Respir ...

Plasma B12 levels tied to anorexia nervosa severity

4 hours ago

(HealthDay)—In patients with anorexia nervosa, plasma levels of vitamin B12 might be an early marker of liver dysfunction and are possibly related to more severe psychopathological aspects, according to a study ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.